中外医学研究
中外醫學研究
중외의학연구
CHINESE AND FOREIGN MEDICAL RESEARCH
2014年
27期
29-30,31
,共3页
孟鲁司特%支原体%肺炎
孟魯司特%支原體%肺炎
맹로사특%지원체%폐염
Montelukast%Mycoplasma%Pneumonia
目的：分析孟鲁司特用于临床辅助治疗小儿肺炎支原体肺炎的疗效及安全性。方法：将2012年3月-2013年9月笔者所在医院收治的78例肺炎支原体肺炎患儿随机分为两组，对照组37例，给予“静滴-口服”阿奇霉素序贯治疗及常规对症口服；试验组41例，在对照组的基础上再加服孟鲁司特，治疗14 d后对两组患儿治疗结果进行综合比较。结果：试验组治疗总有效率(90.24%)明显高于对照组(72.97%)，组间比较差异有统计学意义(P<0.05)；试验组患儿咳嗽、发热、肺部体征等临床症状体征消退所需时间明显少于对照组(P<0.05)。试验组未见孟鲁斯特相关的可疑不良反应。结论：孟鲁司特用于临床辅助治疗小儿肺炎支原体肺炎效果显著，安全性高，值得临床推广应用。
目的：分析孟魯司特用于臨床輔助治療小兒肺炎支原體肺炎的療效及安全性。方法：將2012年3月-2013年9月筆者所在醫院收治的78例肺炎支原體肺炎患兒隨機分為兩組，對照組37例，給予“靜滴-口服”阿奇黴素序貫治療及常規對癥口服；試驗組41例，在對照組的基礎上再加服孟魯司特，治療14 d後對兩組患兒治療結果進行綜閤比較。結果：試驗組治療總有效率(90.24%)明顯高于對照組(72.97%)，組間比較差異有統計學意義(P<0.05)；試驗組患兒咳嗽、髮熱、肺部體徵等臨床癥狀體徵消退所需時間明顯少于對照組(P<0.05)。試驗組未見孟魯斯特相關的可疑不良反應。結論：孟魯司特用于臨床輔助治療小兒肺炎支原體肺炎效果顯著，安全性高，值得臨床推廣應用。
목적：분석맹로사특용우림상보조치료소인폐염지원체폐염적료효급안전성。방법：장2012년3월-2013년9월필자소재의원수치적78례폐염지원체폐염환인수궤분위량조，대조조37례，급여“정적-구복”아기매소서관치료급상규대증구복；시험조41례，재대조조적기출상재가복맹로사특，치료14 d후대량조환인치료결과진행종합비교。결과：시험조치료총유효솔(90.24%)명현고우대조조(72.97%)，조간비교차이유통계학의의(P<0.05)；시험조환인해수、발열、폐부체정등림상증상체정소퇴소수시간명현소우대조조(P<0.05)。시험조미견맹로사특상관적가의불량반응。결론：맹로사특용우림상보조치료소인폐염지원체폐염효과현저，안전성고，치득림상추엄응용。
Objective:To explore curative effect and safety of the auxiliary treatment of Montelukast on pediatric mycoplasma pneumonia.Method:78 cases of children with mycoplasma pneumonia were selected,which were admitted in our hospital from March 2012 to September 2013,they were randomly divided into two groups.In the control group,37 cases were given sequential therapy of “static drop-oral” azithromycin and conventional oral,41 cases in the control group were given Montelukast on the basis of the control group,and then comprehensive compared for the therapeutic outcome of the two groups after 14 days treatment.Result:The total effective rate of experimental group(90.24%) was significantly higher than the control group(72.97%),and the difference between two groups was statistically significant(P<0.05),the experimental group was less than the control group on the fade time of clinical signs,such as cough,fever, lung signs(P<0.05).There was no adverse reaction related to Montelukast.Conclusion:The effect of the auxiliary treatment of Montelukast on pediatric mycoplasma pneumonia is remarkable,and high safety,worthy of clinical popularization and application.
